VIA
IMDX

Vantage Investment Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Vantage Investment Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed – – 798
2018
Q1 		$0 Hold
1
– – ﹤0.01% 838
2017
Q4 		$0 Hold
1
– – ﹤0.01% 845
2017
Q3 		$0 Hold
1
– – ﹤0.01% 815
2017
Q2 		$0 Hold
1
– – ﹤0.01% 790
2017
Q1 		$0 Hold
1
– – ﹤0.01% 796
2016
Q4 		$0 Hold
1
– – ﹤0.01% 838
2016
Q3 		$0 Hold
1
– – ﹤0.01% 819
2016
Q2 		$0 Hold
1
– – ﹤0.01% 876
2016
Q1 		$0 Buy
+1
New +$89 ﹤0.01% 833

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WJA
Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

Vantage Investment Advisors's IMDX Position: Q2 2018 in Review

Vantage Investment Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2018, closing a stake of 1 share.

Vantage Investment Advisors first reported a position in IMDX in Q1 2016 and held it in 9 quarters. The position peaked at $0 in Q1 2018. 33 funds tracked by Wall St. Rank hold IMDX as of Q2 2018.

  • Vantage Investment Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2018 after selling out during the quarter.
  • Vantage Investment Advisors sold 1 Insight Molecular Diagnostics share in Q2 2018.
  • Vantage Investment Advisors first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 9 quarters.
  • Vantage Investment Advisors's Insight Molecular Diagnostics position peaked at $0 in Q1 2018.
  • 33 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2018.

Based on Vantage Investment Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.